Table 1.
Demographic Features, Comorbidities, Sign and Symptoms, Medication and Outcomes of COVID-19 Patients with Oral Candidiasis.
| Demographic | Age (Mean SD)(range) years | 56.55 ± 15.56 (24-96) | |
|---|---|---|---|
| Percentage | Number | ||
| Gender; Male/Female | 56/64 | 46.67/53.3 | |
| Diabetes | 35 | 29.16 | |
| Hypertension | 31 | 25.8 | |
| Cardiovascular disease | 26 | 21.7 | |
| Dyslipidemia | 22 | 18.3 | |
| Hypothyroidism | 11 | 9.2 | |
| Cerebral vascular accident | 4 | 3.3 | |
| Chronic obstructive pulmonary disease | 4 | 3.3 | |
| Chronic kidney disease | 3 | 2.5 | |
| Cancer | 3 | 2.5 | |
| Asthma | 2 | 1.7 | |
| Chronic liver disease | 2 | 1.7 | |
| Sign and symptoms | Dyspnea | 84 | 70 |
| Myalgia | 79 | 65.8 | |
| Fever | 67 | 55.8 | |
| No appetite | 52 | 43.3 | |
| Cough | 51 | 42.5 | |
| Chills | 36 | 30 | |
| Productive cough | 33 | 27.5 | |
| Headache | 30 | 25 | |
| Nausea/vomiting | 28 | 23.3 | |
| Diarrhea | 18 | 15 | |
| Chest Pain | 17 | 14.2 | |
| Sore Throat | 15 | 12.5 | |
| Sweating | 13 | 10.8 | |
| C-reactive protein positive | 78 | 65 | |
| Lymphopenia | 41 | 34.2 | |
| Anemia | 41 | 34.2 | |
| Leukopenai | 28 | 23.3 | |
| Thrombocytopenia | 12 | 10 | |
| Neutropenia | 2 | 1.7 | |
| Nsaids | 120 | 100 | |
| Medications for COVID-19 | All Corticosteroid therapy | 107 | 89.16 |
| IV corticosteroid therapy | 104 | 86.66 | |
| Enoxaparin | 99 | 82.5 | |
| Antiviral therapy | 86 | 71.7 | |
| Broad spectrum antibiotics | 66 | 55 | |
| Spray corticosteroid therapy | 36 | 30 | |
| Outcomes | ICU admission | 10 | 8.3 |
| Invasive mechanical ventilation | 10 | 8.3 | |
| Non-invasive mechanical ventilation | 105 | 87.5 | |
| Duration of hospitalization (days): Mean ± SD | 8.22 ± 3.95 | ||
| All-cause mortality | 1 | 0.8 | |